Axsome Logo.png
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
September 16, 2021 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Logo.png
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine
September 14, 2021 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Logo.png
Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
August 23, 2021 06:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Logo.png
Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 09, 2021 07:05 ET | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
Axsome Logo.png
Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression
August 09, 2021 07:00 ET | Axsome Therapeutics, Inc.
AXS-05 significantly delayed the time to relapse of depression compared to placebo (p=0.002, primary endpoint) AXS-05 significantly prevented relapse of depression over at least 6 months compared to...
Axsome Logo.png
Axsome Therapeutics to Report Second Quarter 2021 Financial Results on August 9, 2021
July 15, 2021 07:00 ET | Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, August 9, 2021 at 8:00 AM Eastern Time NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Logo.png
Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia
June 15, 2021 07:00 ET | Axsome Therapeutics, Inc.
        Submission anticipated in 4Q 2022 NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 07:00 ET | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
axsomelogo-468x57.jpg
Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health Month
May 07, 2021 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) is joining Mental Health America (MHA) and other advocacy organizations in observing May is Mental Health Month,...
axsomelogo-468x57.jpg
Axsome Therapeutics to Report First Quarter 2021 Financial Results on May 10, 2021
April 27, 2021 07:00 ET | Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, May 10, 2021 at 8:00 AM Eastern Time NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...